

CORRECTIONS | VOLUME 9, ISSUE 6, E55, JUNE 01, 2021

Correction to *Lancet Respir Med* 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00160-0](https://doi.org/10.1016/S2213-2600(21)00160-0)

Published: April 14, 2021 • DOI: [https://doi.org/10.1016/S2213-2600\(21\)00181-8](https://doi.org/10.1016/S2213-2600(21)00181-8) PlumX Metrics

Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00160-0](https://doi.org/10.1016/S2213-2600(21)00160-0)—In this Article, the findings section of the summary should have read, “For the per-protocol population (n=139), the primary outcome occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group”. Additionally, in the Summary and Results, the dose of budesonide should have been 400 µg per actuation, to a total dose (two puffs to be taken twice per day) of 1600 µg. These corrections have been made to the online version as of April 14, 2021, and the printed version is correct.

Article Info



ation History



Published: April 14, 2021

Identification

DOI: [https://doi.org/10.1016/S2213-2600\(21\)00181-8](https://doi.org/10.1016/S2213-2600(21)00181-8)

Copyright

© 2021 Elsevier Ltd. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Linked Articles

[Inhaled budesonide in the treatment of early COVID-19 \(STOIC\): a phase 2, open-label, randomised controlled trial](#)

- [Full-Text](#)
- [PDF](#)

THE LANCET



LANCET JOURNALS

The Lancet

The Lancet Child & Adolescent Health

The Lancet Diabetes & Endocrinology

The Lancet Digital Health

The Lancet Gastroenterology & Hepatology

The Lancet Global Health



ancet Haematology

The Lancet Healthy Longevity

The Lancet HIV

The Lancet Infectious Diseases

The Lancet Microbe

The Lancet Neurology

The Lancet Oncology

The Lancet Planetary Health

The Lancet Psychiatry

The Lancet Public Health

The Lancet Regional Health – Americas

The Lancet Regional Health – Europe

The Lancet Regional Health – Western Pacific

The Lancet Respiratory Medicine

The Lancet Rheumatology

EBioMedicine

EClinicalMedicine

CLINICAL INITIATIVES

The *Lancet* Clinic


Commissions

Series

Picture Quiz

GLOBAL HEALTH INITIATIVES

Global Health Portal



Series

Global Burden of Disease

Climate Countdown

MULTIMEDIA

Infographics

Podcasts

Videos

INFORMATION

About us

For authors

For advertisers

For press

Publishing excellence

Careers

Conferences

Community guidelines

ACCESS

Access our content

Register an account

My account

Personal subscriptions

Open Access

Existing print subscribers



Get institutional access

[CONNECT](#)

Lancet alerts

Contact us

Customer service

We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the [Cookie Settings](#) for this site.

Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

[Privacy Policy](#) [Terms and Conditions](#)

